Pharma Stocks
-
Is TAK-881’s Reduced-Volume PID Infusion Data Altering The Investment Case For Takeda (TSE:4502)?
Earlier this month, Takeda Pharmaceutical reported that its pivotal Phase 2/3 trial of investigational PID therapy TAK-881 met its primary…
Read More » -
Zealand Pharma – Execution framework for share buy-back program
Zealand Pharma Company announcement No. 15 / 2026 Zealand Pharma – Execution framework for share buy-back program Copenhagen, Denmark, May…
Read More » -
A Look At Phathom Pharmaceuticals (PHAT) Valuation After Narrower Losses And Reaffirmed Profitability Timeline
Phathom Pharmaceuticals (PHAT) recently reported first quarter results showing a net loss of US$30.37 million, alongside reaffirmed 2026 guidance that…
Read More » -
Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why
What Happened? Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 5.4% in the afternoon session after the company reported strong…
Read More » -
Vertex Pharmaceuticals Stock: Q1 2026 Revenue Hits $2.99B With Full-Year Guidance Intact
Key Stats Current Price: $424 (May 5, 2026) Q1 2026 Revenue: $2.99B, up 8% YoY Q1 2026 Non-GAAP EPS: $4.47, up 10% YoY…
Read More » -
Is It Too Late To Consider Merck (MRK) After A 48% One-Year Gain?
This article examines whether Merck, at around US$113 per share, still offers value or if most of the upside is…
Read More » -
Pfizer’s First PROTAC Approval Adds New Dimension To Oncology Story
FDA approves VEPPANU (vepdegestrant), co developed by Arvinas and Pfizer, as the first PROTAC protein degrader therapy for advanced ER+/HER2,…
Read More » -
Assessing Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Pullback
Event overview and recent stock context Agios Pharmaceuticals (AGIO) has drawn attention after a recent share price pullback, with the…
Read More » -
A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Q1 Beat, Raised 2026 Guidance And Buyback News
Indivior Pharmaceuticals (INDV) is back on investors’ radars after a busy stretch that combined strong Q1 2026 results, a raised…
Read More » -
Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings
Healthcare royalties company Royalty Pharma (NASDAQ: RPRX) will be reporting earnings this Wednesday before market hours. Here’s what investors should…
Read More »